高崎総合医療センター英文論文一覧（2023）#腫瘍学

α-FAtE：切除不能肝細胞癌に対するアテゾリズマブとベバシズマブの併用療法に対す
る新たな奏効予測スコアについての論文
Rossari F, Tada T, Suda G, Shimose S, Kudo M, Yoo C, Cheon J, Finkelmeier F,
Lim HY, Presa J, Masi G, Bergamo F, Amadeo E, Vitiello F, Kumada T,
Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Iavarone M,
Cabibbo G, Montes M, Foschi FG, Vivaldi C, Soldà C, Sho T, Niizeki T, Nishida
N, Steup C, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K,
Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S,
Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N,
Kawata K, Hiraoka A, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A,
Nagano T, Itokawa N, Okubo T, Imai M, Kosaka H, Naganuma A, Koizumi Y,
Nakamura S, Kaibori M, Iijima H, Hiasa Y, Persano M, Burgio V, Piscaglia F,
Scartozzi M, Cascinu S, Casadei-Gardini A, Rimini M
α-FAtE: A new predictive score of response to atezolizumab plus
bevacizumab for unresectable hepatocellular carcinoma
Int J Cancer. 2023 NOV 23;
Journal Impact Factor 2021: 7.316

PMID: 37994647 DOI: 10.1002/ijc.34799 WoS: WOS:001109387300001#腫瘍学

肝細胞癌患者におけるアテゾリズマブ＋ベバシズマブとレンバチニブの肝機能への影響を比較した：混合効果回帰モデルによるアプローチについての論文
Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J,
Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T,
Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Yokohama K, Nishikawa H,
Nishimura T, Shimada N, Kawata K, Kosaka H, Naganuma A, Yata Y, Ohama
H, Kuroda H, Tanaka K, Tanaka T, Tada F, Nouso K, Morishita A, Tsutsui A,
Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S,
Kaibori M, Iijima H, Hiasa Y, Kudo M, Kumada T, Real-Life Practice Experts
HCC REL, HCC 48 Grp Hepatocellular Carcinom

Comparing the impact of atezolizumab plus bevacizumab and lenvatinibon the liver function in hepatocellular carcinoma patients: A mixedeffects regression model approach
Cancer Med. 2023 NOV 21;
Journal Impact Factor 2021: 4.711

PMID: 37987139 DOI: 10.1002/cam4.6726 WoS: WOS:001108372300001#医学 #一般医療 #内科学

ペムブロリズマブによる腫瘍変異の多い転移性胆嚢癌の治療の成功についての論文
Uehara S, Naganuma A, Furuichi N, Furusawa A, Kaburagi T, Naruse
H, Tomaru S, Sano N, Suzuki Y, Masuda T, Hoshino T, Yasuoka
H, Tanaka Y, Saito S, Hatanaka T, Kakizaki S
Successful Treatment of Metastatic Gallbladder Carcinoma with a High
Tumor Mutational Burden Using Pembrolizumab
Intern Med. 2023;62(21):3151-3156.
Journal Impact Factor 2021: 1.282

PMID: 36927965 DOI: 10.2169/internalmedicine.161023 WoS: WOS:001107157700001#歯科学 #口腔外科 #口腔内科

顎変形症患者の顎矯正手術の術前頭頸部 MRI における偶発所見についての論文
Narita M, Yamamoto M, Takaki T, Iwamoto M, Wakoh M, Yakushiji T,
Katakura A, Takano M, Kamio T
Incidental findings on preoperative head and neck MRI for orthognathic
surgery in jaw deformity patients
J Oral Maxillofac Surg Med Pathol. 2024 JAN;36(1):28-33.
Journal Impact Factor 2021: N/A

DOI: 10.1016/j.ajoms.2023.06.008 WoS: WOS:001092806300001#腫瘍学

根治的膀胱摘出術後の長期生存転帰の予測モデルについての論文
Ohtsu A, Arai S, Fujizuka Y, Miyazawa Y, Nomura M, Sekine Y, Koike H, Matsui
H, Shibata Y, Ito K, Suzuki K
Predictive models of long-term survival outcomes following radical
cystectomy
Cancer Med. 2023 DEC;12(23):21118-21128.

Journal Impact Factor 2021: 4.711

PMID: 37902172 DOI: 10.1002/cam4.6670 WoS: WOS:001092418100001#心臓 #循環器系 #症例報告

心膜性びまん性大細胞型 B 細胞リンパ腫と滲出性収縮性心膜炎における ST 上昇の変化を伴うブルガダ表現型：症例報告についての論文
Ishibashi Y, Zhang SS, Tamura S, Ishii H
Brugada phenocopy with altered ST-segment elevation in pericardial
diffuse large B-cell lymphoma and effusive-constrictive pericarditis: acase report
Eur Heart J-Case Rep. 2023 OCT 5;7(10)Journal Impact Factor 2021: N/A

PMID: 37854103 DOI: 10.1093/ehjcr/ytad463 WoS: WOS:001085313900005#腫瘍学Child-Pugh クラス B の肝細胞癌患者に対するアテゾリズマブ＋ベバシズマブとレン
バチニブの実臨床における比較試験についての論文
Ohama H, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M,
Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H,
Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S,
Shimada N, Kawata K, Naganuma A, Kosaka H, Matono T, Shibata H, Aoki T,
Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai
T, Imai M, Koizumi Y, Nakamura S, Iijima H, Kaibori M, Hiasa Y, Kudo M,
Kumada T, Real-life Practice Expe, HCC 48 Grp Hepatocellul
Comparison between Atezolizumab Plus Bevacizumab and Lenvatinib for
Hepatocellular Carcinoma in Patients with Child-Pugh Class B in RealWorld Clinical Settings
Oncology. 2023 SEP;101(9):542-552.
Journal Impact Factor 2021: 3.734

PMID: 37552968 DOI: 10.1159/000530028 WoS: WOS:001044661000001#医学 #一般医療 #内科学

切除不能肝細胞癌患者に対するアテゾリズマブ-ベバシズマブの有効性と安全性：系統的レビューとメタ解析についての論文

Kulkarni AV, Tevethia H, Kumar K, Premkumar M, Muttaiah MD, Hiraoka A,
Hatanaka T, Tada T, Kumada T, Kakizaki S, Vogel A, Finn RS, Rao PN, Pillai
A, Reddy DN, Singal AG
Effectiveness and safety of atezolizumab-bevacizumab in patients withunresectable hepatocellular carcinoma: a systematic review and metaanalysis
EClinicalMedicine. 2023 SEP;63
Journal Impact Factor 2021: 17.033

PMID: 37680945 DOI: 10.1016/j.eclinm.2023.102179 WoS: WOS:001071998
300001#消化器病学 #肝臓学

中等度肝細胞癌患者におけるアテゾリズマブ＋ベバシズマブとレンバチニブの予後への影響の比較についての論文
Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M,
Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H,
Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S,
Shimada N, Kawata K, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A,
Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A,
Matono T, Aoki T, Kuroda H, Yata Y, Koizumi Y, Nakamura S, Kaibori M, Iijima
H, Hiasa Y, Kudo M, Real-life Practice Experts HCC, Hepatocellular Carcinoma
Experts
Comparison of prognostic impact of atezolizumab plus bevacizumab
versus lenvatinib in patients with intermediate-stage hepatocellular
carcinoma
Liver Int. 2023 OCT 3;
Journal Impact Factor 2021: 8.754

PMID: 37789669 DOI: 10.1111/liv.15753 WoS: WOS:001078593600001#腫瘍学

アテゾリズマブとベバシズマブの併用療法を受けた肝細胞癌患者の予後予測における腫瘍マーカースコアの有用性：多施設共同レトロスペクティブ研究についての論文
Tanaka K, Tsuji K, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J,
Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Ishikawa T, Tajiri K, Ochi
H, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N,
Kawata K, Naganuma A, Kosaka H, Matono T, Kuroda H, Yata Y, Ohama H,

Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai
T, Yokohama K, Nishikawa H, Imai M, Koizumi Y, Nakamura S, Iijima H,
Kaibori M, Hiasa Y, Kumada T, Real Life Practice Experts HCC, HCC 48 Grp
Usefulness of Tumor Marker Score for Predicting the Prognosis of
Hepatocellular Carcinoma Patients Treated with Atezolizumab Plus
Bevacizumab: A Multicenter Retrospective Study
Cancers. 2023 SEP;15(17)Journal Impact Factor 2021: 6.575

PMID: 37686624 DOI: 10.3390/cancers15174348 WoS: WOS:001064124100
001
#腫瘍学

レンバチニブ投与中の肝細胞癌患者における食道胃静脈瘤出血の発生率と予測因子についての論文Iavarone M, Alimenti E, Tada T, Shimose S, Suda G, Yoo C, Soldà C, Piscaglia
F, Tosetti G, Marra F, Vivaldi C, Conti F, Schirripa M, Iwamoto H, Sho T, Lee
SH, Rizzato MD, Tonnini M, Rimini M, Campani C, Masi G, Foschi F, Bruccoleri
M, Kawaguchi T, Kumada T, Hiraoka A, Atsukawa M, Fukunishi S, Ishikawa T,
Tajiri K, Ochi H, Yasuda S, Toyoda H, Hatanaka T, Kakizaki S, Kawata
K, Tada F, Ohama H, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A,
Casadei-Gardini A, Lampertico P
Incidence and predictors of esophagogastric varices bleeding in patientswith hepatocellular carcinoma in lenvatinib
Liver Cancer. 2023 SEP 14;
Journal Impact Factor 2021: 12.43

DOI: 10.1159/000534127 WoS: WOS:001074417500001#医学 #一般医療 #内科学 #症例報告

外傷性小腸穿孔によるカンジダ性肋軟骨炎：症例報告についての論文
Nakamura H, Makiguchi T, Tsunoda A, Shirabe K, Yokoo S
Candida Costochondritis Induced by Traumatic Small Bowel Perforation:
A Case Report
Cureus J Med Sci. 2023 AUG 22;15(8)Journal Impact Factor 2021: N/A

PMID: 37746406 DOI: 10.7759/cureus.43923 WoS: WOS:001064958000023

#消化器病学 #肝臓学

食道胃静脈瘤を有する切除不能肝細胞癌患者に対するアテゾリズマブ＋ベバシズマブ
治療の有効性と安全性についての論文
Tada F, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M,
Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H,
Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N,
Kawata K, Naganuma A, Kosaka H, Matono T, Kuroda H, Yata Y, Ohama H,
Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T,
Yokohama K, Nishikawa H, Imai M, Koizumi Y, Nakamura S, Iijima H, Kaibori
M, Hiasa Y, Kumada T, Real Life Practice Experts HCC REL, HCC 48 Grp
Hepatocellular Carcinom
Efficacy and safety of atezolizumab plus bevacizumab treatment for
unresectable hepatocellular carcinoma patients with esophageal-gastricvarices
J Gastroenterol. 2023 NOV;58(11):1134-1143.
Journal Impact Factor 2021: 6.772

PMID: 37528255 DOI: 10.1007/s00535-023-020262 WoS: WOS:001040874600001#腫瘍学

ペムブロリズマブとカルボプラチンおよびパクリタキセル/Nab-パクリタキセルの併用療法を受ける非小細胞肺癌患者における予後栄養指標の予後の可能性についての論文
Nishihara-Kato F, Imai H, Tsuda T, Wasamoto S, Nagai Y, Kishikawa T, Miura
Y, Ono A, Yamada Y, Masubuchi K, Osaki T, Nakagawa J, Umeda Y,
Minemura H, Kozu Y, Taniguchi H, Ohta H, Kaira K, Kagamu H
Prognostic Potential of the Prognostic Nutritional Index in Non-Small
Cell Lung Cancer Patients Receiving Pembrolizumab Combination
Therapy with Carboplatin and Paclitaxel/Nab-Paclitaxel
Oncology. 2023 AUG 18;
Journal Impact Factor 2021: 3.734

PMID: 37598676 DOI: 10.1159/000533604 WoS: WOS:001063547700001#臨床神経学 #多施設共同研究

頚椎椎弓形成術と術後 30 日の合併症の傾向：1095 例の患者を対象とした後方視的多施設研究からの 10 年間の結果についての論文

Takasawa E, Iizuka Y, Mieda T, Inoue H, Kimura A, Takeshita K, Sonoda H,
Takakura K, Sorimachi Y, Ara T, Arai A, Shida K, Nakajima T, Tsutsumi S,
Arai H, Moridaira H, Taneichi H, Funayama T, Noguchi H, Miura K, Kobayashi
R, Iizuka H, Chazono M, Chikuda H
Trends in cervical laminoplasty and 30-day postoperative complications:
10-year results from a retrospective, multi-institutional study of 1095
patients
Eur Spine J. 2023 OCT;32(10):3575-3582.
Journal Impact Factor 2021: 2.721

PMID: 37624437 DOI: 10.1007/s00586-023-079022 WoS: WOS:001063578800001#腫瘍学

切除不能肝細胞がんに対する Atezolizumab+Bevacizumab のリアルワールドデー
タ：IMbrave150 試験参加基準の遵守は予後にどう影響するのか？についての論文
Rimini M, Persano M, Tada T, Suda G, Shimose S, Kudo M, Cheon J,
Finkelmeier F, Lim HY, Presa J, Masi G, Yoo C, Lonardi S, Piscaglia F, Kumada
T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Pressiani T,
Montes M, Vivaldi C, Soldà C, Hiraoka A, Sho T, Niizeki T, Nishida N, Steup C,
Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E,
Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa
C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F,
Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T,
Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M,
Iijima H, Hiasa Y, Burgio V, Rimassa L, Scartozzi M, Cascinu S, CasadeiGardini A
Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable
Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial
Inclusion Criteria Impact Prognosis?
Target Oncol. 2023 MAR;18(2):221-233.
Journal Impact Factor 2021: 4.897

PMID: 36920648 DOI: 10.1007/s11523-023-00953x WoS: WOS:000950092300001

#腫瘍学

アテゾリズマブ＋ベバシズマブで治療した進行肝細胞癌の生存率予測における予後栄
養指標の役割についての論文
Mara P, Rimini M, Tada T, Suda G, Shimose S, Kudo M, Cheon J, Finkelmeier
F, Lim HY, Ramos JP, Masi G, Yoo C, Lonardi S, Stefanini B, Kumada T,
Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Montes M, Vivaldi
C, Soldà C, Hiraoka A, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M,
Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji
K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T,
Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouso K,
Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka
H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Burgio
V, Della Corte A, Ratti F, De Cobelli F, Aldrighetti L, Scartozzi M, Cascinu S,
Casadei-Gardini A
Role of the prognostic nutritional index in predicting survival inadvanced hepatocellular carcinoma treated with atezolizumab plus
bevacizumab
Oncology. 2023 MAY;101(5):283-291.
Journal Impact Factor 2021: 3.734

PMID: 36657420 DOI: 10.1159/000528818 WoS: WOS:000919297200001#医学 #一般医療 #内科学 #症例報告

濾胞性リンパ腫に対するオビヌツズマブとベンダムスチン治療中に SARS-CoV-2 感
染が遷延した：症例報告についての論文
Kambe R, Sato M, Uehara D, Iizuka Y, Kakizaki S
Prolonged SARS-CoV-2 infection during obinutuzumab andbendamustine treatment for follicular lymphoma: A case report
Clin Case Rep. 2023 SEP;11(9)Journal Impact Factor 2021: N/A

PMID: 37649899 DOI: 10.1002/ccr3.7861 WoS: WOS:001057457800001#薬理学 #薬学 #レビュー論文

核内受容体のリン酸化：新規性と治療的意義についての論文
Shindo S, Kakizaki S, Sakaki T, Kawasaki Y, Sakuma T, Negishi M, Shizu R
Phosphorylation of nuclear receptors: Novelty and therapeutic
implications

Pharmacol Ther. 2023 AUG;248
Journal Impact Factor 2021: 13.4

PMID: 37330113 DOI: 10.1016/j.pharmthera.2023.108477 WoS: WOS:00105
4991100001#消化器病学 #肝臓学

αフェト蛋白産生大型十二指腸腺癌の一剖検例についての論文
Hirota S, Naganuma A, Kobayashi R, Suzuki Y, Hoshino T, Yasuoka
H, Tanaka Y, Uraoka T, Kakizaki S
An autopsy case of alpha-fetoprotein-producing large duodenal
adenocarcinoma
Clin J Gastroenterol. 2023 AUG 18;
Journal Impact Factor 2021: N/A

PMID: 37594614 DOI: 10.1007/s12328-023-018435 WoS: WOS:001050498600001#消化器病学 #肝臓学

アテゾリズマブ＋ベバシズマブ治療を受けた肝細胞癌における栄養状態の使いやすい
評価ツールとしての老年栄養リスク指数についての論文Hìraoka A, Kùmada T, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M,
Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H,
Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S,
Shimada N, Kawata K, Naganuma A, Kosaka H, Matono T, Kuroda H, Yata Y,
Ohama H, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N,
Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Iijima H, Kaibori M, Hiasa Y,
Real-Life Practice Experts HCC
Geriatric nutritional risk index as an easy-to-use assessment tool for
nutritional status in hepatocellular carcinoma treated with atezolizumab
plus bevacizumab
Hepatol Res. 2023 OCT;53(10):1031-1042.
Journal Impact Factor 2021: 4.942

PMID: 37306040 DOI: 10.1111/hepr.13934 WoS: WOS:001023573200001

#腫瘍学

ペムブロリズマブとプラチナ製剤およびペメトレキセドの併用療法を受けた非扁平上皮非小細胞肺癌患者の転帰を予測するための好中球対リンパ球比の使用についての論文
Imai H, Wasamoto S, Tsuda T, Nagai Y, Kishikawa T, Masubuchi K, Osaki T,
Miura Y, Umeda Y, Ono A, Minemura H, Yamada Y, Nakagawa J, Kozu Y,
Taniguchi H, Ohta H, Kasai T, Kaira K, Kagamu H
Using the neutrophil-to-lymphocyte ratio to predict the outcome ofindividuals with nonsquamous non-small cell lung cancer receiving
pembrolizumab plus platinum and pemetrexedThorac Cancer. 2023 SEP;14(25):2567-2578.
Journal Impact Factor 2021: 3.223

PMID: 37469246 DOI: 10.1111/17597714.15036 WoS: WOS:001033435500001#腫瘍学 #多施設共同研究

胃癌に対するニボルマブの有効性を炎症ベースの予後スコアを用いて検討：多施設共同レトロスペクティブ研究についての論文
Nakazawa N, Sohda M, Tateno K, Watanabe T, Kimura A, Kogure N, Hosaka
H, Naganuma A, Sekiguchi M, Saito K, Ogata K, Sano A, Sakai M, Ogawa H,
Shirabe K, Saeki H
Examining the Efficacy of Nivolumab for Gastric Cancer Focusing on
Using an Inflammation-based Prognostic Score: A Multicenter
Retrospective Study
Anticancer Res. 2023 FEB;43(2):927-934.
Journal Impact Factor 2021: 2.435

PMID: 36697068 DOI: 10.21873/anticanres.16236 WoS: WOS:001043563900
030#腫瘍学 #多施設共同研究

アテゾリズマブとベバシズマブによる進行肝細胞癌治療における酪酸産生腸内細菌の効果についての論文
Nouso K, Shiota S, Fujita R, Wakuta A, Kariyama K, Hiraoka A, Atsukawa M,
Tani J, Tada T, Nakamura S, Tajiri K, Kaibori M, Hirooka M, Itobayashi
E, Kakizaki S, Naganuma A, Ishikawa T, Hatanaka T, Fukunishi S, Tsuji K,

Kawata K, Takaguchi K, Tsutsui A, Ogawa C, Ochi H, Yata Y, Kuroda H, Iijima
H, Matono T, Shimada N, Yasuda S, Toyoda H, Kumada T
Effect of butyrate-producing enterobacteria on advanced hepatocellular
carcinoma treatment with atezolizumab and bevacizumab
Cancer Med. 2023 SEP;12(17):17849-17855.
Journal Impact Factor 2021: 4.711

PMID: 37563961 DOI: 10.1002/cam4.6416 WoS: WOS:001046503200001#血液学

日本血栓止血学会と国際血栓止血学会による播種性血管内凝固診断基準の予後予測値の比較における純再分類指数：多施設共同前向きコホート研究についての論文
Mori H, Harada-Shirado K, Kawano N, Hayakawa M, Seki Y, Uchiyama T,
Yamakawa K, Ishikura H, Irie Y, Nishio K, Yada N, Okamoto K, Ikezoe T
Net reclassification index in comparison of prognostic value ofdisseminated intravascular coagulation diagnostic criteria by JapaneseSociety on Thrombosis and Hemostasis and International Society on
Thrombosis and Haemostasis: a multicenter prospective cohort study
Thromb J. 2023 AUG 7;21(1)Journal Impact Factor 2021: 5.509

PMID: 37544993 DOI: 10.1186/s12959-023-005231 WoS: WOS:001042040800001#腫瘍学

肝細胞癌患者におけるアテゾリズマブ＋ベバシズマブまたはレンバチニブ一次治療後の順次療法についての論文
Persano M, Rimini M, Tada T, Suda G, Shimose S, Kudo M, Cheon J,
Finkelmeier F, Lim HY, Presa J, Masi G, Yoo C, Lonardi S, Tovoli F, Kumada T,
Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Niizeki T, Montes
M, Vivaldi C, Soldà C, Stefanini B, Hiraoka A, Sho T, Nishida N, Steup C,
Iavarone M, Di Costanzo G, Marra F, Tamburini E, Cabibbo G, Foschi FG,
Silletta M, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K,
Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S,
Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N,
Kawata K, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T,
Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y,

Nakamura S, Kaibori M, Iijima H, Hiasa Y, Campani C, Amadeo E, Rossari F,
Burgio V, Cascinu S, Scartozzi M, Casadei-Gardini A
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib
first-line treatments in hepatocellular carcinoma patients
Eur J Cancer. 2023 AUG;189
Journal Impact Factor 2021: 10.002

PMID: 37385069 DOI: 10.1016/j.ejca.2023.05.021 WoS: WOS:00103547680
0001#臨床神経学経蝶形骨下垂体手術における頸動脈間距離の意義：磁気共鳴画像法による研究についての論文
Tsuneoka H, Tosaka M, Yamaguchi R, Tanaka Y, Mukada N, Shimauchi-Ohtaki
H, Aihara M, Shimizu T, Yoshimoto Y
The Significance of the Intercarotid Distances for Transsphenoidal
Pituitary Surgery: A Magnetic Resonance Imaging Study
World Neurosurg. 2023 JUL;175:E704-E712.
Journal Impact Factor 2021: 2.21

PMID: 37044207 DOI: 10.1016/j.wneu.2023.04.009 WoS: WOS:0010288838
00001
#腫瘍学

切除不能肝細胞癌に対するアテゾリズマブ＋ベバシズマブ療法後の 2 次治療としてのレンバチニブ-臨床結果は肝予備機能の重要性を示すについての論文
Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M,
Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H,
Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S,
Shimada N, Kawata K, Naganuma A, Kosaka H, Matono T, Kuroda H, Yata Y,
Ohama H, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N,
Okubo T, Arai T, Yokohama K, Imai M, Koizumi Y, Nakamura S, Iijima H,
Kaibori M, Hiasa Y, Real-Life Practice Experts HCC RE, HCC Grp Hepatocellular
Carcinoma
Lenvatinib as second-line treatment after atezolizumab plus
bevacizumab for unresectable hepatocellular carcinoma -clinical results
show importance of hepatic reserve function
Oncology. 2023 OCT;101(10):624-633.

Journal Impact Factor 2021: 3.734

PMID: 37307798 DOI: 10.1159/000531316 WoS: WOS:001010234000001#消化器病学 #肝臓学

潰瘍性大腸炎の高齢患者における完全整腸剤と大腸内視鏡検査の安全性：実際の多施設共同後方視的コホート研究についての論文
Hashimoto Y, Kuribayashi S, Itoi Y, Satou K, Nakata K, Kasuga K, Tanaka H,
Hosaka H, Masuo T, Maruhashi K, Furuya K, Masuda T, Takahashi K,
Yamazaki S, Iwamoto A, Uraoka T
Safety of full bowel preparation and colonoscopy in elderly patients withulcerative colitis: A real-world multicenter retrospective cohort study
DEN Open. 2023 JUL 23;4(1)PMID: 37492188 DOI: 10.1002/deo2.275 WoS: WOS:001031544200001#麻酔学

日本周術期アナフィラキシー疫学調査（前向き全国調査）：臨床症状、重症度、治療薬についての論文
Suigiyama Y, Takazawa T, Watanabe N, Bito K, Fujiyoshi T, Hamaguchi S,
Haraguchi T, Horiuchi T, Kamiya Y, Maruyama N, Masumo H, Nakazawa H,
Nagumo K, Orihara M, Sato J, Sekimoto K, Takahashi K, Uchiyama M,
Takahashi K, Yamaguchi M, Kawamata M
The Japanese Epidemiologic Study for Perioperative Anaphylaxis, aprospective nationwide study: clinical signs, severity, and therapeutic
agentsBr J Anaesth. 2023 JUL;131(1):170-177.
Journal Impact Factor 2021: 11.719

PMID: 36967279 DOI: 10.1016/j.bja.2023.02.023 WoS: WOS:001027064700
001#臨床神経学

急性虚血性脳卒中と併発した頸部内頸動脈狭窄または閉塞の管理：経皮的血管形成術とステントのどちらが適切か？についての論文
Kojima T, Aihara M, Naito I, Shimizu T, Miyamoto N, Yamaguchi R, Aishima
K, Sato K, Shimauchi-Ohtaki H, Shintoku R, Wakabayashi K, Yoshimoto Y

Management of Cervical Internal Carotid Artery Stenosis or Occlusion in
Tandem Lesion with Acute Ischemic Stroke: Which Is More Appropriate
Percutaneous Transluminal Angioplasty or Stent?
World Neurosurg. 2023 JUL;175:E208-E217.
Journal Impact Factor 2021: 2.21

PMID: 36924889 DOI: 10.1016/j.wneu.2023.03.054 WoS: WOS:0010271240
00001
#腫瘍学

治療法の選択に役立つ人工知能を用いた肝細胞癌予後予測システム構築の試みについての論文
Hiraoka A, Kumada T, Tada T, Toyoda H, Kariyama K, Hatanaka T, Kakizaki
S, Naganuma A, Itobayashi E, Tsuji K, Ishikawa T, Ohama H, Tada F, Nouso
K
Attempt to establish prognostic predictive system for hepatocellular
carcinoma using artificial intelligence for assistance with selection oftreatment modality
Liver Cancer. 2023 MAY 25;
Journal Impact Factor 2021: 12.43

PMID: 38058420 DOI: 10.1159/000530078 WoS: WOS:001010241400001#生物学

ラットの部分肝照射は肝細胞増殖を介して非照射肝葉の肥大を誘導する&DAG;
Adachi T, Yoshida Y, Shibuya K, Sato K, Yamazaki Y, Kakizaki S, Uraoka T,
Takahashi A
Partial liver irradiation in rats induces the hypertrophy of nonirradiatedliver lobes through hepatocyte proliferation&DAG;
J Radiat Res. 2023 JUL 18;64(4):693-701.
Journal Impact Factor 2021: 2.438

PMID: 37427542 DOI: 10.1093/jrr/rrad051 WoS: WOS:001022338400001#生化学 #分子生物学

各種肝疾患におけるキサンチン酸化還元酵素活性の新規測定法の開発についての論文
Sato K, Naganuma A, Nagashima T, Arai Y, Mikami Y, Nakajima Y, Kanayama
Y, Murakami T, Uehara S, Uehara D, Yamazaki Y, Murase T, Nakamura T,
Uraoka T

A Newly Developed Method-Based Xanthine Oxidoreductase Activities in
Various Human Liver Diseases
Biomedicines. 2023 MAY 14;11(5)Journal Impact Factor 2021: 4.757

PMID: 37239117 DOI: 10.3390/biomedicines11051445 WoS: WOS:00101134
3000001#消化器病学 #肝臓学

肝細胞癌患者におけるアテゾリズマブ＋ベバシズマブによる一次全身療法の影響についての論文
Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M,
Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H,
Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S,
Shimada N, Kawata K, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A,
Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A,
Matono T, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Real-Life
Practice Experts HCC, Hepatocellular Carcinoma Experts
Impact of first-line systemic therapy with atezolizumab plus
bevacizumab in patients with hepatocellular carcinoma
J Gastroenterol Hepatol. 2023 AUG;38(8):1389-1397.
Journal Impact Factor 2021: 4.369

PMID: 37231943 DOI: 10.1111/jgh.16225 WoS: WOS:001001359100001#消化器病学 #肝臓学

アテゾリズマブとベバシズマブを投与された肝細胞癌患者の臨床転帰とプロトンポン
プ阻害薬および抗生物質の使用との関連：多施設共同解析についての論文
Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J,
Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T,
Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Shimada N,
Kawata K, Kosaka H, Naganuma A, Yata Y, Tanaka T, Ohama H, Tada F,
Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai
M, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Kumada T, Real-life
Practice Experts, HCC 48 Grp
Association of proton pump inhibitor and antibiotic use with the clinicaloutcomes of hepatocellular carcinoma patients receiving atezolizumab
and bevacizumab: A multicenter analysis

Hepatol Res. 2023 AUG;53(8):737-748.
Journal Impact Factor 2021: 4.942

PMID: 37020416 DOI: 10.1111/hepr.13905 WoS: WOS:000979449300001#泌尿器学 #腎臓学 #症例報告

肉眼的血尿と尿路閉塞による急性腎障害を伴った腎移植片の動静脈瘻：症例報告についての論文
Aoki Y, Kawamura T, Shiraga N, Yonekura T, Maeda M, Kurihara S, Sekine Y,
Shishido S, Sakai K
Arteriovenous fistula in a renal allograft with gross hematuria andsubsequent acute kidney injury due to urinary tract obstruction: a casereportBMC Nephrol. 2023 JUN 5;24(1)Journal Impact Factor 2021: 2.585

PMID: 37277729 DOI: 10.1186/s12882-023-031835 WoS: WOS:000999742000001#外科学

3D-CT イメージングによる肺の解剖学的再検討についての論文
Nakazawa S, Nagashima T, Kawatani N, Gedeon PC, DeSimone AK, Igai
H, Kosaka T, Shirabe K
Anatomy of the lung revisited by 3D-CT imaging
Video-Assist Thorac Surg. 2023 MAY 24;
Journal Impact Factor 2021: N/A

PMID: 37711275 DOI: 10.21037/vats-23-21 WoS: WOS:000996428100001#微生物学 #レビュー論文

慢性 E 型肝炎ウイルス感染の診断，病態生理，治療-免疫不全患者を対象とすることについての論文Takakusagi S, Kakizaki S, Takagi H
The Diagnosis, Pathophysiology, and Treatment of Chronic Hepatitis E
Virus Infection-A Condition Affecting Immunocompromised Patients
Microorganisms. 2023 MAY 16;11(5)Journal Impact Factor 2021: 4.926

PMID: 37317277 DOI: 10.3390/microorganisms11051303 WoS: WOS:000997
174300001

#公衆衛生学 #環境衛生学 #労働衛生学

子宮頸癌の局所再発における膣腔細胞診の有用性についての論文
Nakamura K, Yamashita S, Kigure K, Nishimura T, Ito I, Azuma A, Nakao K,
Ando K, Kanuma T
Utility of vaginal vault cytology in the local recurrence of cervical cancer
BMC Womens Health. 2023 APR 20;23(1)Journal Impact Factor 2021: 2.742

PMID: 37081439 DOI: 10.1186/s12905-023-023717 WoS: WOS:000975268900001#医学 #研究 #実験 #多施設共同研究

胃がんにおけるニボルマブ治療感受性のマーカーとしてのアルブミン由来の好中球対リンパ球比スコア：多施設共同研究についての論文
Nakazawa N, Sohda M, Tateno K, Watanabe T, Kimura A, Kogure N, Hosaka
H, Naganuma A, Sekiguchi M, Saito K, Ogata K, Sano A, Sakai M, Ogawa H,
Shirabe K, Saeki HAlbumin-derived Neutrophil-to-Lymphocyte Ratio Score as a Marker ofNivolumab Treatment Sensitivity in Gastric Cancer: A Multicenter Study
In Vivo. 2023 MAR-APR;37(2):818-824.
Journal Impact Factor 2021: 2.406

PMID: 36881071 DOI: 10.21873/invivo.13147 WoS: WOS:000961578500040#腫瘍学

高齢の進行性非小細胞肺がん患者におけるプラチナ製剤ダブルト併用療法の臨床的有用性：国立病院機構による前向き多施設共同研究についての論文
Shimokawa M, Kanazu M, Saito R, Mori M, Tamura A, Okano Y, Fujita Y, Endo
T, Motegi M, Takata S, Kita T, Sukoh N, Mizuki F, Takenoyama M, Atagi S
Clinical benefit of platinum doublet combination therapy in older adults
with advanced non-small cell lung cancer: A prospective multicenter
study by the National Hospital Organization in Japan
Thorac Cancer. 2023 JUN;14(17):1597-1605.
Journal Impact Factor 2021: 3.223

PMID: 37073452 DOI: 10.1111/17597714.14904 WoS: WOS:000974326100001

#臨床神経学

ポリグリシン封入体を伴う神経細胞核内封入体症の臨床的、放射線的、分子生物学的解析についての論文
Furuta M, Sato M, Kasahara H, Tsukagoshi S, Hirayanagi K, Fujita Y, Takai E,
Aihara Y, Okamoto K, Ikeda Y
Clinical, radiological, and molecular analyses of neuronal intranuclear
inclusion disease with polyglycine inclusions
J Neurol Sci. 2023 MAY 15;448
Journal Impact Factor 2021: 4.553

PMID: 37001413 DOI: 10.1016/j.jns.2023.120618 WoS: WOS:000972360800
001
#呼吸器系

肺葉切除術とセグメント切除術を併用した場合の臨床病理学的特徴および手術成績：
コホート研究についての論文
Nakazawa S, Shimizu K, Yazawa T, Kawatani N, Obayashi K, Ohtaki Y, Kosaka
T, Yajima T, Shirabe K
Clinicopathological features and surgical outcomes of lobectomy
combined with segmentectomy: a cohort study
J Thorac Dis. 2023 MAR;15(3):1075-+.
Journal Impact Factor 2021: 3.005

PMID: 37065588 DOI: 10.21037/jtd-22-696 WoS: WOS:000953721900001#腫瘍学 #レビュー論文

中期の肝細胞癌に対する治療戦略：経動脈的化学塞栓療法、全身療法、転換療法についての論文
Hatanaka T, Yata Y, Naganuma A, Kakizaki S
Treatment Strategy for Intermediate-Stage Hepatocellular Carcinoma:
Transarterial Chemoembolization, Systemic Therapy, and Conversion
Therapy
Cancers. 2023 MAR;15(6)Journal Impact Factor 2021: 6.575

PMID: 36980684 DOI: 10.3390/cancers15061798 WoS: WOS:000954182100
001

#消化器病学 #肝臓学

肝細胞癌に対する atezolizumab-bevacizumab 治療後に発症した免疫関連低下垂体症の 3 例についての論文
Furuichi N, Naganuma A, Kaburagi T, Suzuki Y, Hoshino T, Shibusawa N,
Horiguchi S, Hatanaka T, Kakizaki S, Uraoka T
Three cases of immune-related hypopituitarism after atezolizumabbevacizumab treatment for hepatocellular carcinoma
Clin J Gastroenterol. 2023 JUN;16(3):422-431.
Journal Impact Factor 2021: N/A

PMID: 36821067 DOI: 10.1007/s12328-023-017750 WoS: WOS:000937662900002#腫瘍学

超音波ガイド下における肝細胞癌のアブレーション治療における体重過多と臨床成績の関係。レトロスペクティブ分析についての論文
Hatanaka T, Yata Y, Saito N, Nakano S, Nakano Y, Hazama Y, Yoshida S,
Hachisu Y, Tanaka Y, Yoshinaga T, Naganuma A, Kakizaki S
Relationship between Being Overweight and Clinical Outcomes ofAblation Therapy for Hepatocellular Carcinoma under UltrasoundGuidance: A Retrospective Analysis
Cancers. 2023 FEB;15(4)Journal Impact Factor 2021: 6.575

PMID: 36831630 DOI: 10.3390/cancers15041289 WoS: WOS:000938354200
001#消化器病学 #肝臓学

アテゾリズマブ＋ベバシズマブ治療後に炭素イオン放射線治療が奏功した肝細胞癌の2 例についての論文
Takakusagi S, Tanaka H, Naganuma A, Kakizaki S, Shibuya K, Ohno T,
Takagi H, Uraoka T
Two cases of hepatocellular carcinoma successfully treated by carbon
ion radiotherapy after atezolizumab plus bevacizumab treatment
Clin J Gastroenterol. 2023 JUN;16(3):407-415.
Journal Impact Factor 2021: N/A

PMID: 36750524 DOI: 10.1007/s12328-023-01768z WoS: WOS:000928921800001

#腫瘍学

アテゾリズマブとベバシズマブの併用療法を受けた肝細胞癌患者における脾臓容積の増加（レンバチニブとの比較）。レトロスペクティブな解析についての論文
Hatanaka T, Naganuma A, Furusawa A, Tamura Y, Saito N, Suzuki
Y, Hoshino T, Yata Y, Uraoka T, Kakizaki S
Increased Spleen Volume in Hepatocellular Carcinoma Patients Treatedwith Atezolizumab plus Bevacizumab in Comparison to Lenvatinib: A
Retrospective Analysis
Oncology. 2023 MAR;101(3):193-202.
Journal Impact Factor 2021: 3.734

PMID: 36649691 DOI: 10.1159/000528081 WoS: WOS:000916774000001